source
- Avalo Therapeutics reports Phase 2 success in inflammatory skin disorder and secures $375M financingAvalo Therapeutics announced on May 6, 2026 that its experimental immunology drug met its primary endpoints in a Phase 2 study of an inflammatory skin condition. The trial tested two dose levels,…
- Novo Nordisk reports 1 million Wegovy patients and 2.3 bn DKK sales in Q1 amid pricing pressureNovo Nordisk's CEO Mike Doustad said the company saw about one million patients using its obesity drug Wegovy during the first quarter. The pill generated sales of roughly 2.3 billion Danish krone…